CVS Health has agreed to pay $315 million to resolve federal allegations that it unlawfully filled medically unnecessary opioid prescriptions and billed Medicare and Medicaid. The October 13, 2026 settlement stems from a 2024 lawsuit accusing CVS of distributing over 12 billion opioid doses from 2015 to 2020 while ignoring signs of pill mills. CVS denies wrongdoing and agreed to implement enhanced Drug Enforcement Administration oversight mechanisms.
Overview of the $315 million settlement
- ▪CVS Health stated that it disagreed with the U.S. Justice Department's allegations of illegally filling opioid prescriptions and admitted no wrongdoing as part of the $315 million settlement
- ▪The $315 million settlement resolves a federal lawsuit filed against CVS Health in 2024 in federal court in Rhode Island, which originated as a whistleblower complaint by a former CVS employee
- ▪CVS Health agreed to pay $315 million to resolve federal allegations that it unlawfully filled medically unnecessary opioid prescriptions and submitted false claims to federal healthcare programs
Allegations in the federal lawsuit
- ▪The 2024 federal lawsuit alleged that CVS Health's poor staffing levels, performance metrics, and incentive compensation policies forced pharmacists to race to fill opioid prescriptions without confirming their legitimacy
- ▪A 2024 Justice Department lawsuit noted that CVS Health was among the top opioid dispensers in the United States, selling over 12 billion doses from 2015 to 2020
- ▪The U.S. Justice Department alleged that CVS Health violated the federal Controlled Substances Act since 2013 by filling invalid opioid prescriptions, including high doses from known pill mills
- ▪The U.S. Justice Department alleged that CVS Health violated the False Claims Act by seeking payment from federal healthcare programs, including Medicare and Medicaid, for invalid opioid prescriptions
CVS defense of pharmacists
- ▪CVS Health stated in 2024 that its pharmacists were being held to vague, undefined, and ever-changing standards of practice when filling prescription opioids
- ▪CVS Health stated that its more than 27,000 pharmacists were highly trained in medication safety and supported by best-in-class programs to make appropriate patient decisions
New operational safeguards and monitoring
- ▪As part of the $315 million settlement of opioid prescription claims announced October 13, 2026, CVS Health entered into an agreement with the Drug Enforcement Administration to establish processes for monitoring and receiving reports of illegal dispensing
- ▪Under the Drug Enforcement Administration agreement reached as part of the $315 million settlement, CVS Health must evaluate doctors suspected of illegally prescribing opioid painkillers
Wider opioid crisis litigation
- ▪Over the past decade, drugmakers, wholesalers, and pharmacies have agreed to U.S. government settlements totaling over $50 billion to address an overdose crisis linked to more than 100,000 annual U.S. deaths
- ▪In August 2026, rival pharmacy chain Walmart agreed to pay $50 million to resolve a 2020 federal lawsuit alleging it unlawfully dispensed opioid prescriptions
- ▪CVS Health previously agreed to pay close to $5 billion in 2022 to settle thousands of opioid-related claims brought by state, local, and Native American tribal governments
Debatable claims
- ▪Retail pharmacies should be required to screen doctors for suspicious opioid prescribing
- ▪Financial settlements without admission of guilt fail to deter corporate healthcare misconduct
- ▪Retail pharmacies bear equal responsibility with prescribing doctors for the opioid crisis
- ▪Federal opioid dispensing rules impose vague obligations on retail pharmacists
Story comments
Loading comments…